Administration of FGF21 decreased the mRNA expression of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and protected against pathological myocardial remodeling and improved cardiac function at 2 weeks in a myocardial infarction mouse model (65). The gene discussed is FGF21; the disease is myocardial infarction.